22 November 2023
22 November 2023
Ensem will receive an upfront payment and will be eligible for additional payments upon achieving milestones, totalling up to $1.33bn.
The new scheme will launch in 2024 and aims to save the National Health Service (NHS) £14bn over five years.
Merck & Co (MSD) will acquire all outstanding shares of Caraway, which has a preclinical-stage drug portfolio, through a subsidiary.
The decision on the sBLA for Abecma will be delayed beyond the PDUFA target date of 16 December.
Despite FDA issuing a rejection for the drug earlier this year, the European Commission has approved Yorvipath for chronic hypoparathyroidism.
The partnership will augment the AI research programmes of Genentech to speed up the delivery of new therapies.
The introduction of the new Hyrimoz formulation strengthens the biosimilar portfolio of Sandoz in the immunology sector.
The funding will go towards the development of Alto Neuroscience's four CNS candidates, with Phase II study data readouts expected by early 2025.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.
Give your business an edge with our leading industry insights.
